GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE-MKT:SENS), a medical technology company focused on the development and commercialization of Eversense®, a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the pricing of its underwritten offering of 29,078,014 shares of its common stock at a price of $1.41 per share to a group of institutional investors, including Roche Finance, Ltd., which has agreed to purchase 21,276,596 shares in the offering, and funds affiliated with New Enterprise Associates, which have agreed to purchase 7,092,198 shares in the offering. Gross proceeds to Senseonics from the offering are expected to be $41.0 million. The offering is expected to close on or about June 1, 2017, subject to customary closing conditions.

Leerink Partners LLC is acting as the sole book-running manager for the offering.

About Senseonics Holdings, Inc.

Senseonics Holdings, Inc. is a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to help people with diabetes confidently live their lives with ease. Senseonics’ first generation CGM system, Eversense, includes a small sensor, smart transmitter and mobile application. Based on fluorescence sensing technology, the sensor is designed to be inserted subcutaneously and communicate with the smart transmitter to wirelessly transmit glucose levels to a mobile device. After insertion, the sensor is designed to continually and accurately measure glucose levels.